Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Abevmy 25 mg/mL concentrate for solution for infusion., CAPECITABINE VIATRIS 150 mg, comprimé pelliculé, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion
CERO THERAPEUTICS HOLDINGS, INC.
Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)
The George Institute
local advenced pancreatic adenocarcinoma
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN
Genmab A/S
Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).
1 trial -
Abraxane, CAAA614A12101, PACLITAXEL ALBUMIN-BOUND, OXALIPLATIN, FLUOROURACIL, AAA614, IRINOTECAN, AAA514, CALCIUM FOLINATE
Novartis Pharmaceuticals
Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)
1 trial -
Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.
Genmab A/S
Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.
1 trial -
Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Genmab A/S
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
1 trial -
Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
Adaptive Biotechnologies Corp
Chronic Tonal Tinnitus
1 trial -
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
BioMarin Pharmaceutical Australia Pty Ltd
Achondroplasia
1 trial -
Active treatment with a high dose of BGS649
Mereo BioPharma Group plc
Endometriosis
1 trial -
Air médical en bouteille, OXYGEN
Pari Pharma GmbH
Alternating Hemiplegia of Childhood
1 trial -
Alisertib
Takeda
Acute Myelogenous Leukemia
1 trial -
Alkotinib Capsules
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
ALK-positive Non-small Cell Lung Cancer
1 trial -
Alvelestat
Mereo BioPharma Group plc
Covid19
1 trial -
Alvelestat (MPH966)
Mereo BioPharma Group plc
Alpha-1 Antitrypsin Deficiency (AATD)
1 trial -
Alxn1920 placebo product, ALXN1920
Alexion Europe SAS
Primary Mebranous Nephropathy (PMN)
1 trial -
Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance
Sanofi-aventis Healthcare Pty Ltd
Hidradenitis
1 trial -
Amphotericin B
Matinas BioPharma Holdings
Candidiasis, Chronic Mucocutaneous
1 trial -
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Eisai Co.,
HER2 positive or HER2-low metastatic breast cancer
1 trial -
An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors
Ipsen
Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors
1 trial -
An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301
Sanofi-aventis Healthcare Pty Ltd
Asthma
1 trial -
Anlotinib plus Pemetrexed
Henan Provincial People's Hospital
Non-squamous Cell Non-Small Cell Lung Cancer
1 trial -
Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet
Lacuna Pharma Pty Ltd
Idiopathic membranous nephropathy and severe proteinuria
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Advanced Esophageal Squamous Carcinoma
1 trial -
Apexelsin 5 mg/ml powder for dispersion for infusion., FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, OXALIPLATINE KABI 5 mg/ml, solution à diluer pour perfusion., GEMCITABINE HIKMA 38 mg/ml, solution à diluer pour perfusion, FLUOROURACILE TEVA 5000 mg/100 ml, solution à diluer pour perfusion, IRINOTECAN MEDAC 20 mg/ml, solution à diluer pour perfusion
CERO THERAPEUTICS HOLDINGS, INC.
Resectable borderline pancreatic adenocarcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources